Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 26, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Cap	11	15	21	-	-	-
Market Cap Growth	-14.11%	-29.20%	-	-	-	-
Enterprise Value	7.4	10.29	19.61	0	0	0
Last Close Price	0.52	0.71	1.52	-	-	-
PB Ratio	2.20	2.33	4.37	-	-	-
P/TBV Ratio	1.93	2.06	3.61	-	-	-
Debt / Equity Ratio	-	0	0	-0.31	-0.49	-0.33
Debt / FCF Ratio	-	-	-	7.88	-	-
Net Debt / Equity Ratio	-0.69	-0.71	-0.27	-0.26	-0.12	-0.26
Net Debt / EBITDA Ratio	0.63	0.83	0.58	-0.35	-0.35	-0.17
Net Debt / FCF Ratio	0.98	1.31	0.32	6.73	-0.41	-0.74
Quick Ratio	8.53	22.57	1.28	0.04	0.27	0.04
Current Ratio	10.31	27.07	4.20	0.04	0.27	0.04
Return on Equity (ROE)	-100.21%	-97.99%	-192.96%	111.27%	89.51%	284.14%
Return on Assets (ROA)	-97.62%	-90.54%	-69.60%	-171.31%	-63.06%	-492.33%
Return on Invested Capital (ROIC)	-343.81%	-208.14%	-237.75%	133.54%	60.30%	332.95%
Return on Capital Employed (ROCE)	-102.90%	-100.24%	-140.47%	168.29%	64.74%	257.38%
Buyback Yield / Dilution	-55.40%	-62.27%	-9.38%	-1.42%	-11.86%	-63.55%
Total Shareholder Return	-55.40%	-62.27%	-9.38%	-1.42%	-11.86%	-63.55%

Updated May 13, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q